Loading ...
Sorry, an error occurred while loading the content.

MedTRACK: Tysabri poised for return to market

Expand Messages
  • Bill
    MedTRACK: Tysabri poised for return to market PharmaLive.com (press release) -
    Message 1 of 1 , Apr 1, 2006
    • 0 Attachment
      MedTRACK: Tysabri poised for return to market
      <http://www.pharmalive.com/News/index.cfm?articleid=326987&categoryid=10>
      PharmaLive.com (press release) - Newtown,PA,USA
      ... According to MedTRACK, there are 14 products currently in phase III
      trials for multiple sclerosis, and a further 8 ... Biogen Idec's Rituxan
      (rituximab) is another ...

      Genentech and Biogen Idec Submit Supplemental Biologics License ...
      <http://www.pharmalive.com/News/index.cfm?articleid=327476&categoryid=51>
      PharmaLive.com (press release) - Newtown,PA,USA
      ... Administration (FDA) for the use of Rituxan® (Rituximab) as first
      ... needs, including systemic lupus erythematosus, lupus nephritis,
      multiple sclerosis and ANCA ...


      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.